Premium
S odium‐glucose co‐transporter‐2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta‐analysis
Author(s) -
Giugliano Dario,
Longo Miriam,
Caruso Paola,
Maiorino Maria Ida,
Bellastella Giuseppe,
Esposito Katherine
Publication year - 2021
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.14374
Subject(s) - empagliflozin , mace , canagliflozin , medicine , dapagliflozin , type 2 diabetes , diabetes mellitus , meta analysis , adverse effect , cardiology , endocrinology , myocardial infarction , conventional pci
Abstract A meta‐analysis of cardiorenal outcomes of sodium‐glucose co‐transporter‐2 inhibitors (SGLT‐2is) available in Europe or the United States in patients with type 2 diabetes (T2D) is presented. An electronic search up to 6 January 2021 was conducted to determine eligible trials. A total of eight cardiorenal outcomes trials of SGLT‐2is (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin and sotagliflozin) were identified, with 65,587 patients. Data were analysed using a random effects model. Overall, SGLT‐2is were associated with a 12% reduced risk of major adverse cardiovascular events (MACE; HR = 0.88; 95% CI, 0.83–0.93; Q statistic, p = .19), with no significant heterogeneity ( p for interaction = .465) between subgroups of patients with or without cardiovascular disease (CVD). The risk of the composite renal outcome was significantly reduced by treatment with SGLT‐2is (HR = 0.61, 95% CI, 0.54–0.70), with no significant heterogeneity of associations with outcome (I 2 = 37%, p = .11), and no difference in the risk between patients with or without CVD ( p for interaction = .665). SGLT‐2is have moderate benefits on MACE and major benefits on the progression of diabetic kidney disease.